Diagnosis of preterm birth risk and success of induced labour

ended

Context Preterm Birth (PTB) is the birth of a baby before 37 weeks of pregnancy. Problem Preterm Delivery - Leading cause of death in children under 5 years - Affects more than 15 million births a year - Preterm rates are increasing, particularly for extremely preterm birth (less than 28 weeks) - Many survivors face a lifetime of disability, including learning disabilities and visual and hearing problems. - Immediate costs of a PTB are on average 10 (31-34 weeks) to 100 (25-27 weeks) times more than a full-term one. The total cost of PTB in the US was estimated at $26 billion. There are currently no tools that accurately diagnose and predict PreTerm Birth Solution – Fine Birth Fine Birth is an in-vivo diagnostic technology that uses torsional ultrasound to study the shear mechanical properties of the cervix tissue. We can accurately identify if and when a baby will be born prematurely and also quickly and cost effectively identify if a PTB is imminent. By improving the sensitivity of current techniques from 30% to 70%, we can decrease the number of Preterm Birth cases and reduce their impact on patients and health systems. Fine Birth could avoid 369,000 Premature Births and save more than 22,000M € only in USA & Europe by accurately predicting PTB, while saving 800M€ in identifying imminent PTBs. Project We aim to use the feasibility study to test our business model. Furthermore, we aim to hold conversations with different players along the value chain and generate interest. During the phase 2 we aim to clinically validate and certify a POC device and prepare it for sublicensing. Impact & Market By 2024, we aim for Fine Birth to be integrated in 7.5% of the diagnostics ultrasound devices for Obstetrics/ Gynaecology market with sales of 3,115 units, generating sales of 9.3€M and an IRR of 65% based on a total investment of 2€M.